Literature DB >> 2405443

Genetic polymorphism of trimethylamine N-oxidation.

R Ayesh1, R L Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2405443     DOI： 10.1016/0163-7258(90)90074-c

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN： 0163-7258            Impact factor:   12.310


× No keyword cloud information.
  10 in total

Review 1.  Inborn 'errors' of drug metabolism. Pharmacokinetic and clinical implications.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

Review 2.  Molecular basis of polymorphic drug metabolism.

Authors:  A K Daly
Journal:  J Mol Med (Berl)       Date:  1995-11       Impact factor: 4.599

Review 3.  Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism.

Authors:  Sharon K Krueger; David E Williams
Journal:  Pharmacol Ther       Date:  2005-06       Impact factor: 12.310

4.  The fish odour syndrome: biochemical, familial, and clinical aspects.

Authors:  R Ayesh; S C Mitchell; A Zhang; R L Smith
Journal:  BMJ       Date:  1993-09-11

5.  Dimethylethylamine in mould core manufacturing: exposure, metabolism, and biological monitoring.

Authors:  T Lundh; B Ståhlbom; B Akesson
Journal:  Br J Ind Med       Date:  1991-03

6.  Experimental study on the metabolism of dimethylethylamine in man.

Authors:  B Ståhlbom; T Lundh; B Akesson
Journal:  Int Arch Occup Environ Health       Date:  1991       Impact factor: 3.015

7.  Effect of dietary intake of trimethylamine on human metabolism of the industrial catalyst dimethylethylamine.

Authors:  T Lundh; B Akesson; S Skerfving
Journal:  Occup Environ Med       Date:  1995-07       Impact factor: 4.402

8.  The N-oxidation of trimethylamine in a Jordanian population.

Authors:  H F Hadidi; S Cholerton; S Atkinson; Y M Irshaid; N M Rawashdeh; J R Idle
Journal:  Br J Clin Pharmacol       Date:  1995-02       Impact factor: 4.335

Review 9.  Gut Microbiota Modulation as a Novel Therapeutic Strategy in Cardiometabolic Diseases.

Authors:  Yahkub Babatunde Mutalub; Monsurat Abdulwahab; Alkali Mohammed; Aishat Mutalib Yahkub; Sameer Badri Al-Mhanna; Wardah Yusof; Suk Peng Tang; Aida Hanum Ghulam Rasool; Siti Safiah Mokhtar
Journal:  Foods       Date:  2022-08-25

Review 10.  Drug Discovery and Development of Novel Therapeutics for Inhibiting TMAO in Models of Atherosclerosis and Diabetes.

Authors:  Ian Steinke; Nila Ghanei; Manoj Govindarajulu; Sieun Yoo; Juming Zhong; Rajesh H Amin
Journal:  Front Physiol       Date:  2020-10-29       Impact factor: 4.566
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.